TAMPA, Fla., October 24, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being held November 2-4 in Miami.

TAMPA, Fla., September 30, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued the following letter to shareholders from its President and Chief Executive Officer, Kim Murphy.

TAMPA, Fla., August 24, 2022--Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

TAMPA, Fla., June 23, 2022--Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

TAMPA, Fla., June 14, 2022--Oragenics Announces Publication of Positive Data for its NT-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

We've seen this movie before only to watch dip-buyers get fleeced — but money managers are now warming to the idea of a material bounce in stocks.

TAMPA, Fla., April 18, 2022--Oragenics to Participate at the World Vaccine Congress Washington 2022

TAMPA, Fla., April 06, 2022--Oragenics Extends Collaboration to Develop Vaccines against Future Variants of Coronaviruses

TAMPA, Fla., March 25, 2022--Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

TAMPA, Fla., March 22, 2022--Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1